Latest Administration News

EVE Health Group has announced a $1.3 million capital raising through a placement of shares and free attaching options, aimed at advancing its pharmaceutical product rollout and development pipeline. Several components of the offer await shareholder approval at an upcoming general meeting.

Ragnar Metals has confirmed high-grade gold extensions at its Harnäs Project in Sweden through recent channel and rock sampling, with drilling preparations now underway following regulatory approvals.

Merino & Co. Limited has attributed the late lodgement of director interest notices to an administrative oversight and reaffirmed its compliance measures to meet ASX disclosure rules.

Recce Pharmaceuticals is progressing its Phase 3 clinical trial of RECCE 327, a novel synthetic antibiotic targeting multidrug-resistant infections, with interim data from Indonesia supporting registration plans across ASEAN by 2026.

Horizon Oil has released a first supplementary and replacement bidder’s statement for its off-market takeover offer for Cue Energy, proposing a mix of cash and shares that values Cue at a 10-14% premium. The deal aims to create a diversified oil and gas producer across Asia-Pacific with significant synergies.

GR Engineering Services Limited has updated its dividend announcement, confirming a fully franked ordinary dividend of AUD 0.12 per share and setting the Dividend Reinvestment Plan price at AUD 3.9507 with a 2.5% discount.

Imugene Limited has launched a $20 million equity raising comprising a $12 million placement and an $8 million Share Purchase Plan, alongside issuing options, convertible notes, and warrants to support its azer-cel clinical program.

KWB Group reports robust first-half 2026 results, driven by record order volumes and strategic showroom expansion. The company’s capital-light model and proprietary IT upgrades position it well for continued growth in the kitchen renovation market.

Clarity Pharmaceuticals has unveiled compelling Phase II trial results showing its Cu-SAR-bisPSMA PET imaging agent significantly improves detection of prostate cancer recurrence over the current standard. The data, presented at the 2026 European Association of Urology Congress and accepted by European Urology journal, mark a key milestone ahead of regulatory submissions.

First Lithium Limited’s shares have been suspended from trading on the ASX due to a missed reporting deadline, raising questions about the company’s compliance and near-term outlook.

European Resources Limited (ASX: ERE) has announced a $4.26 million renounceable entitlement offer to accelerate exploration and metallurgical work at its Korsnäs rare earth elements project in Finland. The offer is partially underwritten and includes attaching options, providing shareholders with a strategic opportunity amid significant recent resource growth.

Arovella Therapeutics has secured TGA confirmation to advance its Phase 1 trial of ALA-101 in Australia via the efficient Clinical Trial Notification pathway, following FDA clearance in the US.